In this webinar, learn how AI technologies can accelerate oncology drug discovery and enhance the success of anti-cancer agents.
Artificial intelligence is revolutionizing drug discovery as we know it, effectively replacing many high throughput screening studies with computer-generated insights. By integrating predictive AI and machine learning (ML) technologies with in vivo validation, researchers can gain swift and precise drug response insights. Whether you seek to understand a candidate drug molecule’s mechanism of action or explore potential drug synergies, this approach can bring clear and compelling evidence of therapeutic efficacy to your oncology development program.
In this webinar, learn how integrating predictive AI, ML, and advanced cancer models into your drug discovery workflow may give your most promising anti-cancer agents the best chance at translational success.
Key Learning Objectives
- Discover all the ways predictive AI can be applied to accelerate oncology drug discovery and beyond.
- Explore best practices for predictive AI platforms.
- Delve into new preclinical and clinical case studies that pair predictive AI with in vivo validation for more insightful drug response and synergy data.
- Experience our new virtual assistant tool in action — it uses natural language processing (NLP) to easily find tumor models with your desired genetic profiles.
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Presenters
Senior Director
Scientific Engagement and Key Accounts
Certis Oncology Solutions
Michael Boice, PhD, has over 20 years of experience in translational oncology drug development. Michael’s areas of scientific expertise include the development of novel oncology therapeutics, functional genomics and rare cancers. At Certis, he works directly with clients to enhance their discovery efforts through translational science discussions, optimizing the customer experience. He holds a PhD in Pharmacology from Weill Cornell Graduate School of Medical Sciences, Department of Pharmacology Memorial Sloan Kettering Cancer Center, Cancer Biology and Genetics.
Production Partner
Certis Oncology Solutions, Inc.
Certis is an AI-enabled precision oncology and translational science company. Our product is Oncology Intelligence®—highly predictive therapeutic response data derived from advanced models of cancer. We partner with oncology therapeutics developers to help close the problematic translation gap between preclinical studies and clinical trials. Using CertisAI™, our proprietary artificial intelligence/machine learning platform, and more clinically relevant, patient-derived tumor models, we bring certainty to lead candidate selection and help secure clear and compelling evidence of drug efficacy.
Additional Content From Certis Oncology Solutions, Inc.
Combination Therapy for Glioblastoma: A Personalized, AI-Driven Approach
Discover how AI-driven models and patient-derived xenografts are advancing personalized combination therapies for glioblastoma.
Artificial Intelligence in Preclinical Research: Pathology, Biospecimens, and Model Selection
Learn how AI is advancing preclinical research through quantitative pathology, curated biospecimen data, and intelligent tumor model selection in this expert-led webinar.
Leveraging Genomic, Preclinical, and Drug Response Data in the Age of AI
Join Dr. Michael Boice from Certis Oncology for a discussion and demonstration of how artificial intelligence can improve preclinical decision-making in cancer research.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
Related Content
Advancing ADC Development: Leveraging AI and Translational Preclinical Models to Improve Clinical Predictability
Join our webinar to discover how to de-risk ADC development through the integration of AI-driven analytics, mouse clinical trials and specialized translational models.
From Biopsy to Better Decisions: Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Learn how patient-derived organoids predict treatment response in metastatic colorectal cancer and explore findings from the OPTIC study on drug sensitivity and clinical outcomes.
De-Risking Immunotherapy Targets with Next-Gen HLA Discovery Platforms
In this webinar, Rico Buchli, PhD, shares how next-generation soluble HLA peptide discovery platforms can strengthen early immunotherapy R&D - from target identification and confirmation to receptor/drug validation and translational decision-making.